Gene · 8019
Papers2,104
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
361 to 380 of 2,104
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and Treatment. | Cancers (Basel) | 2022 | 36497404 | PubTator, text mining | PubMed |
| CD5L-associated gene analyses highlight the dysregulations, prognostic effects, immune associations, and drug-sensitivity predicative potentials of LCAT and CDC20 in hepatocellular carcinoma. | Cancer Cell Int | 2022 | 36494696 | PubTator, text mining | PubMed |
| Multimodality imaging and treatment of paranasal sinuses nuclear protein in testis carcinoma: A case report. | World J Clin Cases | 2022 | 36483827 | PubTator, text mining | PubMed |
| Extensive Recombination-driven Coronavirus Diversification Expands the Pool of Potential Pandemic Pathogens. | Genome Biol Evol | 2022 | 36477201 | PubTator, text mining | PubMed |
| Arginine methylation of BRD4 by PRMT2/4 governs transcription and DNA repair. | Sci Adv | 2022 | 36475791 | PubTator, text mining | PubMed |
| Targeted Protein Degradation: Design Considerations for PROTAC Development. | Curr Protoc | 2022 | 36469581 | PubTator, text mining | PubMed |
| The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma. | J Immunol Res | 2022 | 36438198 | PubTator, text mining | PubMed |
| Molecular Basis and Rationale for the Use of Targeted Agents and Immunotherapy in Sinonasal Cancers. | J Clin Med | 2022 | 36431263 | PubTator, text mining | PubMed |
| Modulation of Virulence-Associated Traits in Aspergillus fumigatus by BET Inhibitor JQ1. | Microorganisms | 2022 | 36422362 | PubTator, text mining | PubMed |
| Histone acetylation modification regulator-mediated tumor microenvironment infiltration characteristics and prognostic model of lung adenocarcinoma patients. | J Thorac Dis | 2022 | 36389327 | PubTator, text mining | PubMed |
| Super-enhancers in esophageal carcinoma: Transcriptional addictions and therapeutic strategies. | Front Oncol | 2022 | 36387198 | PubTator, text mining | PubMed |
| Case report: Immunovirotherapy as a novel add-on treatment in a patient with thoracic NUT carcinoma. | Front Oncol | 2022 | 36387105 | PubTator, text mining | PubMed |
| Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma. | Neurooncol Adv | 2022 | 36382109 | PubTator, text mining | PubMed |
| Identification of Novel Kinases of Tau Using Fluorescence Complementation Mass Spectrometry (FCMS). | Mol Cell Proteomics | 2022 | 36379402 | PubTator, text mining | PubMed |
| [Susceptibility study on the germline rare variants of bromodomain and extraterminal domain protein family-encoding genes and patients with cancer living in some regions of China]. | Zhonghua Yi Xue Za Zhi | 2022 | 36372767 | PubTator, text mining | PubMed |
| Small Molecule BRD4 Inhibitors Apabetalone and JQ1 Rescues Endothelial Cells Dysfunction, Protects Monolayer Integrity and Reduces Midkine Expression. | Molecules | 2022 | 36364277 | PubTator, text mining | PubMed |
| Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies. | Int J Mol Sci | 2022 | 36362442 | PubTator, text mining | PubMed |
| Translational Implications for Radiosensitizing Strategies in Rhabdomyosarcoma. | Int J Mol Sci | 2022 | 36362070 | PubTator, text mining | PubMed |
| SPOP in Cancer: Phenomena, Mechanisms and Its Role in Therapeutic Implications. | Genes (Basel) | 2022 | 36360288 | PubTator, text mining | PubMed |
| Understanding the Roles of the NSD Protein Methyltransferases in Head and Neck Squamous Cell Carcinoma. | Genes (Basel) | 2022 | 36360250 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8019/papers?page=19